Abstract: Multidrug-resistant Neisseria gonorrhoeae infections have been declared 1 of the top 3 urgent threats to public health. Approaches to combat resistance include targeted therapy with antibiotics previously thought to be ineffective, made possible by rapid molecular assays to predict susceptibility. Previous studies have associated the gyrase A (gyrA) gene of N. gonorrhoeae with in vitro resistance to ciprofloxacin. We conducted a systematic review of studies comparing N. gonorrhoeae gyrA genotype results with conventional antimicrobial susceptibility testing results. We identified 31 studies meeting inclusion criteria, among which 7 different loci for mutations in the gyrA gene were identified, from 16 countries between the years of 1996 and 2016. We then performed a meta-analysis among those studies stratifying by use of real-time polymerase chain reaction (PCR) or non-real-time PCR technique, and compared the summary receiver operating characteristic curves between the 2 PCR methods. Among studies using real-time PCR, the pooled estimate of sensitivity and specificity of gyrA genotype results for the prediction of N. gonorrhoeae susceptibility to ciprofloxacin were 98.2% (95% confidence interval [CI], 96.5-99.1%) and 98.6% (95% CI, 97.0-99.3%), respectively. The summary operating characteristic curves for studies using real-time PCR techniques were well separated from those using non-real-time PCR techniques, with only slight overlap in the CIs, suggesting that real-time PCR techniques were a more accurate approach. GyrA genotype testing is a novel approach to combating the emergence of multidrug-resistant N. gonorrhoeae and is a sensitive and specific method to predict in vitro ciprofloxacin susceptibility.
M ultidrug-resistant Neisseria gonorrhoeae infections have been declared 1 of the top 3 urgent threats to public health. 1 N. gonorrhoeae has developed resistance to all antimicrobials currently available, 2, 3 and there are only a few novel antibiotics in development [4] [5] [6] ; therefore, new approaches are urgently needed. A recently described approach calls for targeted therapy with antibiotics previously thought to be ineffective, 7, 8 which has been made possible by the development of rapid molecular assays that predict in vitro antimicrobial susceptibility. 9 In the United States, it is estimated that approximately 80% of N. gonorrhoeae infections are susceptible to ciprofloxacin. 10 Previous work has shown that mutation of the gyrase A (gyrA) gene of Neisseria species is associated with ciprofloxacin resistance, particularly mutation at the Ser91 codon 9 [30s, http:// links.lww.com/OLQ/A163]. Mutations in other loci have been shown to confer resistance to ciprofloxacin, such as parC, however prior studies have demonstrated that mutations in other locations, which confer resistance, usually occur in parallel with the gyrA mutation; prediction of ciprofloxacin susceptibility, therefore, may be done solely by detection of mutation in the gyrA gene [30s-34s, http://links.lww.com/OLQ/A163]. In response, realtime polymerase chain reaction (PCR)-based molecular assays have been developed to predict gonococcal susceptibility to ciprofloxacin [33s, http://links.lww.com/OLQ/A163].
Those rapid molecular genotypic assays have been studied extensively to determine how they correlate with standard agar dilution susceptibility methods [32s-43s, http://links.lww.com/ OLQ/A163]. Here we review the previously published reports describing the sensitivity, specificity, negative predictive values (NPV) and positive predictive values (PPVs) of the gyrA genotypic assays for the prediction of N. gonorrhoeae susceptibility to ciprofloxacin.
METHODS
In September 2016, we conducted a literature search using the following text-word terms: "GYRA" OR "CIPROFLOXACIN" OR "QUINOLONE" AND "GONORRH*" with PubMed as a search platform. Our search resulted in over 900 studies which was further restricted to 831 in the English language. Our only inclusion criterion was the use of gyrA genotypic determination techniques and the comparison of genotype results with conventional methods for determining ciprofloxacin susceptibility. We excluded articles that only evaluated resistant or susceptible strains of N. gonorrhoeae because there would be no comparison of susceptibility results. Similarly, we excluded articles reporting five or fewer isolates with resistant or susceptible phenotypes. Wild type is defined as the most prevalent sequence of the gyrase A gene, which predicts full ciprofloxacin susceptibility. One article was excluded as a cluster analysis was performed and the results provided were insufficient to distinguish which mutant or wild-type strains were associated with which susceptibility results. In total, we identified 30 articles meeting inclusion criteria. We were also aware of 1 article that was not available on PubMed, which fulfilled inclusion criteria. Here, we report sensitivity, specificity, PPVand NPVof the wild-type gyrA gene for predicting susceptibility to ciprofloxacin from those 31 reports.
Statistical Analysis
Sensitivity, specificity and their corresponding 95% confidence intervals (CI) of individual studies were calculated and known correlation between the pair of sensitivity and specificity, we obtained the summary statistics of sensitivity and specificity by using a bivariate random effects modeling approach. 12 The summary operating characteristic curves (sROC) 13 were constructed and compared between studies using real-time PCR techniques and non-real-time PCR techniques (Fig. 3 ). All the statistical analyses were conducted using Package MADA (Meta-Analysis of Diagnostic Accuracy) in the R statistical software environment version 3.3.1.
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RESULTS
Of the 31 articles meeting inclusion criteria, 7 different loci for mutations in the gyrA gene were identified from samples collected in 16 countries between the years of 1996 and 2016 [30s-60s, http://links.lww.com/OLQ/A163]. Eleven studies used real-time polymerase chain reaction techniques for determination of the gyrA genotype, whereas 20 were conducted using other methods, such as pyrosequencing, probe hybridization, isothermic chimeric primer-initiated amplification, or gel electrophoresis to determine the gyrA genotype.
All studies compared genotype results with minimum inhibitory concentration (MIC) assay results using agar dilution techniques, except 1 study, which used available phenotypic susceptibility data without MIC assay results [40s, http:// links.lww.com/OLQ/A163]. The cutoff MIC for reduced susceptibility and resistance varied slightly among studies with cutoff values ranging from ≥ 0.06 to 0.125 μg/mL and ≥ 0.05 to 1.0 μg/mL, respectively.
Studies Using Non-Real-Time Polymerase Chain Reaction Methods for Determination of GyrA Genotype
We identified 20 studies (N = 2931 isolates) from 7 countries using non-real-time PCR techniques for the determination of the gyrA genotype. The range of sensitivities and specificities of wild-type gyrA genotype for predicting ciprofloxacin susceptibility reported by those studies was 58.0% to 100% (mean, 91.2%) and 90.5% to 100% (mean, 99.2%), respectively (Figs. 1A and B) . Positive predictive values ranged from 76.3% to 100% (mean, 97.9%), whereas NPVs ranged from 72.4% to 100% (mean, 95.4%). The pooled estimate of sensitivity and specificity based on the bivariate mixed-effect modeling approach were 91.7% (95% CI, 85.4-95.5%) and 98.0% (95% CI, 96.7-98.8%), respectively. Gharizadeh et al. found 10 isolates with mutations in the gyrA gene (2 in region Asp95 and 8 in region Ser91) that showed phenotypic susceptibility to ciprofloxacin; however, the median MIC was higher than for wild-type strains (0.21 and 0.03 μg/mL, respectively). Conversely, Grad et al. report 5 isolates with phenotypic resistance to ciprofloxacin (MIC values > 1 μg/mL) that had no identifiable mutation in gyrA or parC.
Fourteen of the 20 studies included sequence analysis of parC as well as gyrA. Figure 3 shows the sROC for studies using non-real-time PCR and real-time PCR techniques.
DISCUSSION
We systematically reviewed studies that have compared Neisseria gonorrhoeae gyrA genotype results with conventional methods of ciprofloxacin susceptibility determination. Among studies using real-time PCR techniques there appears to be strong evidence that gyrA genotype results are both highly sensitive and specific for the prediction of N. gonorrhoeae susceptibility to ciprofloxacin. Furthermore, studies have shown that gyrA genotype determined by real-time PCR is 100% specific to N. gonorrhoeae compared to other Neisseria subspecies [35s-37s, 41s, http://links. lww.com/OLQ/A163].
Studies using non-real-time PCR techniques, such as Pyrosequencing and probe hybridization, reported wider ranges of sensitivities. That finding is likely in part due to the incorporation of multiple different mutations in the gyrA gene that may not be associated with resistance; the range of sensitivities improved when only analyzing known resistance mutations. Notably, the study by Gharizadeh et al. compared gyrA mutation with phenotypic susceptibility results; when looking at MIC assay results, it was noted that samples with mutant gyrA genotypes had higher median MICs than wild-type samples.
We also compared the sROC between studies using realtime PCR and non-real-time PCR techniques. The summary estimates of sensitivity and specificity were well separated, though the confidence regions overlapped slightly. Based on that, we therefore conclude that the real-time PCR technique may be a more accurate technique in gyrase A genotype testing than other techniques.
Rapid molecular assays for determination of resistance are enabling targeted antimicrobial therapy that could curb the emergence of antimicrobial resistance. The FDA-approved molecular assay for Mycobacterium tuberculosis uses real-time PCR for amplification and molecular probes for the detection of mutations within the rifampin-resistance determining region. That assay has an overall sensitivity of 97.6% and specificity between 98.1% and 99.2%. 15 Real-time PCR amplification of known resistance genes has also been shown to be clinically effective in Figure 3 . Summary operating characteristic curves for sensitivity and specificity comparing studies using non-real-time PCR and real-time PCR techniques for the determination of the gyrase A genotype. Solid and dashed circled areas represent the 95% confidence regions for studies using real-time PCR and non-realtime PCR techniques, respectively. screening for Methicillin-resistant Staphylococcus aureus, with low false-negative and false-positive rates between 0.0-7.3% and 0.0-5.4% respectively. 16 Additionally, rapid molecular assays are available for carbapenem-resistant Enterobacteriaceae and have been shown to detect most resistance genes without yielding false positives. 17 Therefore, given the robust performance of the real-time PCR gyrA assays, N. gonorrhoeae genotyping of gyrA has the potential to enable reliable targeted therapy with ciprofloxacin. Targeted therapy with ciprofloxacin might reduce the ongoing selection pressure caused by the widespread empiric use of extended-spectrum cephalosporins and have implications for the enhanced control of ceftriaxone resistant N. gonorrhoeae.
8
A recent study suggested that treatment might be a major driver of ceftriaxone resistance among N. gonorrhoeae.
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In November 2015, University California Los Angeles implemented routine gyrA testing on all N. gonorrhoeae positive clinical specimens. Results from testing are used to promote targeted therapy with ciprofloxacin based on genotype susceptibility results. 19, 20 Further studies are underway to characterize the impact of the assay on patient clinical outcomes. 21 There were a few limitations to our study. Primarily this was an analysis of previous studies and therefore subject to the same limitations as the studies being reviewed. Additionally the prevalence of ciprofloxacin susceptible N. gonorrhoeae differs in various regions of the world, 10, 22 and gyrA results may not be of substantial benefit in regions where the prevalence of ciprofloxacin resistance is very high. Furthermore, our study spanned 20 years, during which time technological advances likely impacted the sensitivity and specificity of test results. However, as most studies, including the earliest studies, report high sensitivity and specificity of gyrA testing for predicting ciprofloxacin susceptibility, the changes in technology likely did not impact the overall findings, but furthered the utility of gyrA testing, and therefore support, rather than negate our findings.
CONCLUSIONS
Gyrase A genotype testing is a novel approach to combating the emergence of multi drug-resistant N. gonorrhoeae. Among studies comparing gyrA genotype results with conventional methods of susceptibility testing, there appeared to be strong evidence that gyrA genotype results are both sensitive and specific in predicting ciprofloxacin in vitro susceptibility, with real-time PCR techniques being a more accurate approach compared with non-real-time PCR techniques.
